{"id":2425,"date":"2020-10-09T17:21:45","date_gmt":"2020-10-09T14:21:45","guid":{"rendered":"https:\/\/www.intheranostics.com\/prof\/?page_id=2425"},"modified":"2020-10-09T17:35:46","modified_gmt":"2020-10-09T14:35:46","slug":"liver-tumors","status":"publish","type":"page","link":"https:\/\/www.intheranostics.com\/prof\/en\/liver-tumors\/","title":{"rendered":"Liver Tumors"},"content":{"rendered":"

[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.4.8″ background_color=”rgba(0,0,0,0)” background_image=”https:\/\/www.intheranostics.com\/wp-content\/uploads\/2020\/06\/metastatik_prostat_kanseri.jpg” custom_padding=”100px||100px||false|false” locked=”off”][et_pb_fullwidth_header title=”Liver Tumors” text_orientation=”center” content_max_width_last_edited=”off|desktop” _builder_version=”4.4.8″ title_font_size=”50px” content_font_size=”41px” subhead_font=”|700|||||||” subhead_font_size=”38px” subhead_line_height=”1.1em” background_enable_color=”off” background_enable_image=”off” custom_margin=”||||false|false” custom_padding=”||||false|false” animation_style=”slide” animation_direction=”bottom”][\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.4.8″ custom_margin=”0px||0px||false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_row _builder_version=”4.4.8″ custom_margin=”0px||||false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”4.4.8″][et_pb_divider divider_weight=”0px” _builder_version=”4.4.8″ use_background_color_gradient=”on” background_color_gradient_start=”#8dd2e1″ background_color_gradient_end=”#23afca” background_color_gradient_direction=”90deg” width=”50%” module_alignment=”center” height=”10px”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″][et_pb_row admin_label=”row” _builder_version=”4.4.8″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”||||false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.4.8″]Most of the\u00a0liver tumors<\/strong>\u00a0cannot be surgically removed because of their large size or proximity to life-threatening structures. Sometimes, the disease can cause small but many tumors to spread to the liver. In this case, surgery is both very risky and not practical. Surgical removal is not possible in two-thirds of primary liver cancer patients and more than 90 percent of patients with metastatic (secondary) liver cancer for these reasons. In patients with inoperable liver cancer, one of the treatment options is Yttrium-90 microsphere treatment.
\n[\/et_pb_text][et_pb_accordion disabled_on=”on|on|on” _builder_version=”4.4.8″ disabled=”on”][et_pb_accordion_item title=”TEDAV\u0130 PLANLAMASI – 99MTC-MAA KARACI\u011eER PERF\u00dcZYON S\u0130NT\u0130GRAF\u0130S\u0130” open=”on” open_toggle_text_color=”#0ca7c5″ _builder_version=”4.4.8″ toggle_font=”|700|||||||” toggle_font_size=”18px”]<\/p>\n

Tc-99m MAA Karaci\u011fer Perf\u00fczyon Sintigrafisi Nedir, T\u00fcm\u00f6r Oda\u011f\u0131n\u0131 Nas\u0131l G\u00f6sterir?<\/b><\/span><\/p>\n

Teranostik<\/b>; t\u0131p d\u00fcnyas\u0131nda yeni ve geli\u015fmekte olan bir aland\u0131r. G\u00f6r\u00fcnt\u00fcleme ve tedavinin tek bir sistem \u00fczerinden ger\u00e7ekle\u015ftirilmesini esas al\u0131r, spesifik tedaviye ve tedavinin takibine e\u015f zamanl\u0131 olarak izin verir. <\/span><\/p>\n

Karaci\u011fer kanserlerinde, tedavi \u00f6ncesi prova amac\u0131yla yap\u0131lan Tc-99m MAA karaci\u011fer perf\u00fczyon sintigrafisi<\/b> ile akci\u011fer ve mide-ba\u011f\u0131rsak sistemine olan ka\u00e7aklar y\u00fcksek duyarl\u0131l\u0131kta saptanabilmekte ve optimum tedavi dozu planlanabilmektedir. Di\u011fer yandan \u0130trium-90 (Y-90) mikrok\u00fcre tedavisi<\/b> ile bu t\u00fcm\u00f6ral dokular\u0131n hedefe y\u00f6nelik tedavisi yap\u0131labilmektedir. <\/span>Bu, teranostik uygulamalar i\u00e7in olduk\u00e7a ba\u015far\u0131l\u0131 ve yeni bir y\u00f6ntemdir. <\/span><\/p>\n

Karaci\u011fer atardamar\u0131 (hepatik arter) yoluyla yap\u0131lan tedavilerde, karaci\u011ferin iki farkl\u0131 damardan beslenmesi avantaj\u0131ndan faydalan\u0131lmaktad\u0131r. 30 y\u0131l\u0131 a\u015fk\u0131n s\u00fcredir bu fark, kanser ila\u00e7lar\u0131n\u0131n karaci\u011fer damar\u0131 yoluyla uygulanmas\u0131na imkan tan\u0131m\u0131\u015ft\u0131r. Transarteriyel radyoembolizasyon (TARE) olarak da isimlendirilen Y-90 mikrok\u00fcre tedavisi, karaci\u011ferin hem kendisinden kaynaklanan hem de metastatik kanserleri i\u00e7in etkili bir tedavidir ve ameliyat veya di\u011fer b\u00f6lgesel tedavilerin uygulanamad\u0131\u011f\u0131 hastalar\u0131m\u0131zda, takip eden hekiminin \u00f6nerisi ile daha iyi sa\u011f kal\u0131m ve azalm\u0131\u015f hastal\u0131k y\u00fck\u00fcne ula\u015fmak amac\u0131yla kullan\u0131labilir.<\/span><\/p>\n

Bir hasta Y-90 mikrok\u00fcre tedavisi i\u00e7in aday olarak se\u00e7ildikten sonra, ilk olarak anjiyografik de\u011ferlendirme yap\u0131l\u0131r. Bu i\u015flem ile organ anatomisi ve anatomik farkl\u0131l\u0131klar tan\u0131mlan\u0131r, karaci\u011fer dola\u015f\u0131m\u0131 de\u011ferlendirilerek karaci\u011fer harici damarlar\u0131n t\u0131kanmas\u0131\/embolizasyonu ger\u00e7ekle\u015ftirilir. Anjiyografi i\u015flemi ile damar haritalamas\u0131n\u0131n tamamlanmas\u0131n\u0131 takiben, Y-90 mikrok\u00fcre tedavisinin provas\u0131 olan ve akci\u011fer\/mide-ba\u011f\u0131rsak sistemine ka\u00e7aklar\u0131n ara\u015ft\u0131r\u0131ld\u0131\u011f\u0131 ve en uygun tedavi dozunun planlanmas\u0131na imkan sa\u011flayan Tc-99m MAA karaci\u011fer perf\u00fczyon sintigrafisi<\/b> \u00e7al\u0131\u015fmas\u0131 yap\u0131l\u0131r.<\/span><\/p>\n

Tc-99m MAA Karaci\u011fer Perf\u00fczyon Sintigrafisi Kimlere Uygulan\u0131r?<\/b><\/span><\/p>\n

Tc-99m MAA karaci\u011fer perf\u00fczyon sintigrafisi, Y-90 mikrok\u00fcre tedavisine aday olgularda uygulan\u0131r. Tedavi \u00f6ncesi hastaya \u00f6zel planlamay\u0131 m\u00fcmk\u00fcn k\u0131lan, tan\u0131sal anjiyografi i\u015flemi s\u0131ras\u0131nda yap\u0131lan bir g\u00f6r\u00fcnt\u00fcleme y\u00f6ntemidir. <\/span><\/p>\n

Tc-99m MAA Karaci\u011fer Perf\u00fczyon Sintigrafisi G\u00fcvenli midir?<\/b><\/span><\/p>\n

Tc-99m MAA karaci\u011fer perf\u00fczyon sintigrafisi i\u015flemi, d\u00fc\u015f\u00fck dozlarda radyasyonun kullan\u0131ld\u0131\u011f\u0131, g\u00fcvenli bir g\u00f6r\u00fcnt\u00fcleme y\u00f6ntemidir. Birlikte yap\u0131lacak anjiyografi i\u015flemine ait \u00f6neri ve bilgilendirmeler ise size giri\u015fimsel radyoloji uzman\u0131m\u0131z taraf\u0131ndan verilecektir. Her iki i\u015flem, kullan\u0131lan radyasyon nedeniyle hamile hastalar\u0131m\u0131zda kesinlikle uygulanamaz. <\/span><\/p>\n

Tc-99m MAA Karaci\u011fer Perf\u00fczyon Sintigrafisi \u00d6ncesi Haz\u0131rl\u0131k <\/b><\/span><\/p>\n

Tc-99m MAA karaci\u011fer perf\u00fczyon sintigrafisi i\u00e7in \u00f6zel bir hasta haz\u0131rl\u0131\u011f\u0131na gerek yoktur. Bununla birlikte yap\u0131lacak anjiyografi i\u015flemine ait \u00f6neri ve bilgilendirmeler size giri\u015fimsel radyoloji \u00fcnitesi personelimiz taraf\u0131ndan yap\u0131lacakt\u0131r.<\/span><\/p>\n

Tc-99m MAA Karaci\u011fer Perf\u00fczyon Sintigrafisi Nas\u0131l Uygulan\u0131r?<\/b><\/span><\/p>\n

Tc-99m MAA karaci\u011fer perf\u00fczyon sintigrafisi; N\u00fckleer T\u0131p ve Giri\u015fimsel Radyoloji Uzmanlar\u0131n\u0131n birlikte ger\u00e7ekle\u015ftirdikleri, multidisipliner bir uygulamad\u0131r<\/b>.<\/span><\/p>\n

Y-90 mikrok\u00fcre tedavisi \u00f6ncesi temel a\u015famalardan ilki; giri\u015fimsel radyoloji \u00fcnitesinde t\u00fcm\u00f6r\u00fc besleyen damarlar\u0131 de\u011ferlendirmek i\u00e7in yap\u0131lan anjiyografi i\u015flemidir. Bu i\u015flem tamamland\u0131ktan sonra mevcut anjiyografi kateterinden d\u00fc\u015f\u00fck dozda Tc-99m MAA’n\u0131n enjeksiyonu yap\u0131l\u0131r. Bu i\u015flem s\u0131ras\u0131nda herhangi bir \u015fey hissedilmemektedir. Daha sonra akci\u011fer ve karaci\u011ferinizi g\u00f6r\u00fcnt\u00fclemek \u00fczere N\u00fckleer T\u0131p Klini\u011fine transferiniz ger\u00e7ekle\u015ftirilecektir. Bu i\u015flem s\u0131ras\u0131nda gama kamera<\/b> ad\u0131 verilen cihaza ait \u00f6zel yatakta s\u0131rt \u00fcst\u00fc uzanman\u0131z istenecektir. Sintigrafi i\u015flemi tamamland\u0131ktan sonra, anjiyografiye ait takibiniz yap\u0131lacak ve sa\u011fl\u0131k personelimizin bilgi vermesiyle hastaneden g\u00fcvenle ayr\u0131labileceksiniz. <\/span><\/p>\n

\u0130la\u00e7 verildikten sonra ilk 12 saat k\u00fc\u00e7\u00fck \u00e7ocuklarla ve hamile kad\u0131nlarla temastan ka\u00e7\u0131nman\u0131z gerekti\u011fini l\u00fctfen unutmay\u0131n\u0131z. <\/span>G\u00f6r\u00fcnt\u00fcleriniz N\u00fckleer T\u0131p Uzmanlar\u0131m\u0131z taraf\u0131ndan de\u011ferlendirilecek ve tedavi planlaman\u0131z s\u0131ras\u0131nda kullan\u0131lacakt\u0131r. <\/span><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”TEDAV\u0130 H\u0130ZMETLER\u0130 – \u0130TRIYUM-90 MIKROK\u00dcRE TEDAV\u0130S\u0130” open_toggle_text_color=”#0ca7c5″ _builder_version=”4.4.8″ toggle_font=”|700|||||||” toggle_font_size=”18px” open=”off”]<\/p>\n

\u0130triyum-90 Mikrok\u00fcre Tedavisi Nedir, Nas\u0131l Tedavi Eder?<\/b><\/span><\/p>\n

Teranostik <\/b>t\u0131p d\u00fcnyas\u0131nda yeni geli\u015fmekte olan bir aland\u0131r. T\u00fcm\u00f6re \u00f6zg\u00fcl bir ila\u00e7 ile g\u00f6r\u00fcnt\u00fcleme yaparak saptanan t\u00fcm\u00f6r ve metastazlar\u0131n\u0131n, nereye gidece\u011fi-ne kadar gidece\u011fi ve hastal\u0131kl\u0131 dokuyu etkileme g\u00fcc\u00fc \u00f6nceden bilinen yine \u00f6zg\u00fcl bir ila\u00e7 ile tedavi edilebildi\u011fi bir yakla\u015f\u0131md\u0131r. Bu yakla\u015f\u0131m, geleneksel t\u0131ptan ki\u015fiye \u00f6zg\u00fc \u00e7a\u011fda\u015f t\u0131p uygulamalar\u0131na ge\u00e7i\u015f yap\u0131lmas\u0131n\u0131 sa\u011flamaktad\u0131r.<\/span><\/p>\n

Karaci\u011fer kanserlerinde, tedavi \u00f6ncesi prova amac\u0131yla yap\u0131lan 99mTc-MAA karaci\u011fer perf\u00fczyon sintigrafisi<\/b> ile akci\u011fer ve mide-ba\u011f\u0131rsak sistemine olan ka\u00e7aklar y\u00fcksek duyarl\u0131l\u0131kla saptanabilmekte ve optimum tedavi dozu planlanabilmektedir. Di\u011fer yandan \u0130trium-90 (Y-90) mikrok\u00fcre<\/b> tedavisi ile bu t\u00fcm\u00f6ral dokular\u0131n hedefe y\u00f6nelik tedavisi yap\u0131labilmektedir. <\/span>Bu, teranostik uygulamalar i\u00e7in olduk\u00e7a ba\u015far\u0131l\u0131 ve yeni bir y\u00f6ntemdir. <\/span><\/p>\n

Karaci\u011fer atardamar\u0131 (hepatik arter) yoluyla yap\u0131lan tedavilerde, karaci\u011ferin iki farkl\u0131 damardan beslenmesi avantaj\u0131ndan faydalan\u0131lmaktad\u0131r. 30 y\u0131l\u0131 a\u015fk\u0131n s\u00fcredir bu fark, kanser ila\u00e7lar\u0131n\u0131n karaci\u011fer damar\u0131 yoluyla uygulanmas\u0131na imkan tan\u0131m\u0131\u015ft\u0131r. Transarteryel radyoembolizasyon (TARE) olarak da isimlendirilen Y-90 mikrok\u00fcre tedavisi, karaci\u011ferin hem kendisinden kaynaklanan hem de metastatik kanserleri i\u00e7in etkili bir tedavidir ve ameliyat veya di\u011fer b\u00f6lgesel tedavilerin uygulanamad\u0131\u011f\u0131 hastalar\u0131m\u0131zda, takip eden hekiminin \u00f6nerisi ile daha iyi sa\u011f kal\u0131m ve azalm\u0131\u015f hastal\u0131k y\u00fck\u00fcne ula\u015fmak amac\u0131yla kullan\u0131labilir.<\/span><\/p>\n

Y-90, beta radyasyonu yayar ve t\u00fcm\u00f6r b\u00f6lgesine ula\u015ft\u0131\u011f\u0131nda, h\u00fccre \u00f6l\u00fcm\u00fc ve t\u00fcm\u00f6r nekrozuna neden olur. Y-90 izotopunun dokuda ilerlemesi yakla\u015f\u0131k 1 cm’dir ve bu k\u0131sa menzille \u00e7evre sa\u011fl\u0131kl\u0131 karaci\u011fer dokusunun ald\u0131\u011f\u0131 radyasyon dozu hasta lehine s\u0131n\u0131rland\u0131r\u0131lm\u0131\u015f olur. Buna ek olarak, beta radyasyonunun b\u00f6ylesine k\u0131sa menzili, hasta bak\u0131m\u0131n\u0131 yapan t\u0131bbi personel ve aile \u00fcyeleri i\u00e7in de hastay\u0131 daha g\u00fcvenli k\u0131lmaktad\u0131r.<\/span><\/p>\n

\u0130triyum-90 Mikrok\u00fcre Tedavisi Kimlere Uygulan\u0131r?<\/b><\/span><\/p>\n

Y-90 mikrok\u00fcre tedavisi; klasik olarak ameliyatla \u00e7\u0131kart\u0131lamayan, karaci\u011ferin kendisinden kaynaklanan (primer) veya metastatik karaci\u011fer kanserlerinde uygulanmaktad\u0131r.<\/span><\/p>\n

\u0130triyum-90 Mikrok\u00fcre Tedavisi G\u00fcvenli midir?<\/b><\/span><\/p>\n

Y-90 mikrok\u00fcre tedavisi tipik olarak iyi tolere edilen g\u00fcvenli bir tedavidir. <\/span>Y-90; saf beta par\u00e7ac\u0131\u011f\u0131 yayd\u0131g\u0306\u0131 ve gama radyasyonu bulunmad\u0131g\u0306\u0131 i\u00e7in tedavi sonras\u0131 hasta izolasyonu ve \u00f6zel bir radyasyondan korunma \u00f6nlemi gerekmemektedir.<\/span><\/p>\n

Y-90 mikrok\u00fcre tedavisinin en s\u0131k yan etkisi; yorgunluk, bulant\u0131, kusma ve\/veya kar\u0131n a\u011fr\u0131s\u0131 ile karakterize olan post-radyoembolizasyon sendromudur. \u015eikayetler, analjezik ve antiemetik ila\u00e7lar ile kolayl\u0131kla tedavi edilebilir. <\/span><\/p>\n

Ayr\u0131ca, tecr\u00fcbeli eller ile g\u00f6r\u00fclme s\u0131kl\u0131\u011f\u0131 daha da azalabilen, \u00e7ok daha nadir di\u011fer yan etkilere de rastlanabilmektedir. \u0130yi bir tedavi planlama ve \u00f6n planlama anjiyografisinde, ilgili damarlar\u0131n profilaktik embolizasyonu veya uygun kateterizasyon teknikleri ile bu komplikasyonlar\u0131n da \u00f6n\u00fcne ge\u00e7ilebilmektedir. <\/span><\/p>\n

\u0130triyum-90 Mikrok\u00fcre Tedavisi \u00d6ncesi Haz\u0131rl\u0131k <\/b><\/span><\/p>\n

Y-90 mikrok\u00fcre tedavisine uygun hasta se\u00e7imi; genel cerrah, medikal onkolog, gastroenterolog, giri\u015fimsel radyolog ve n\u00fckleer t\u0131p uzman\u0131ndan olu\u015fan multidisipliner t\u00fcm\u00f6r kurulu taraf\u0131ndan yap\u0131lmaktad\u0131r. <\/span><\/p>\n

Tedavi \u00f6ncesinde, ilk ad\u0131m olarak genel sa\u011fl\u0131k durumunuz ve performans\u0131n\u0131z, karaci\u011fer ve b\u00f6brek fonksiyonlar\u0131n\u0131z\u0131 g\u00f6steren kan testi sonu\u00e7lar\u0131n\u0131z, patoloji ve ameliyat raporlar\u0131n\u0131z, daha \u00f6nce ald\u0131\u011f\u0131n\u0131z tedaviler ve g\u00f6r\u00fcnt\u00fclemeleriniz (FDG-PET\/BT, MR, BT vb.) de\u011ferlendirilecektir. <\/span><\/p>\n

Klinik \u00f6n de\u011ferlendirmede tedaviye uygun oldu\u011funuz d\u00fc\u015f\u00fcn\u00fcl\u00fcr ise tedavinizi planlamak amac\u0131yla; anjiyografi \u00fcnitesi ve n\u00fckleer t\u0131p klini\u011finde karaci\u011fer damarlar\u0131n\u0131za y\u00f6nelik anjiyografi ve karaci\u011fer perf\u00fczyon sintigrafisi \u00e7al\u0131\u015fmalar\u0131 ger\u00e7ekle\u015ftirilecektir. Her iki i\u015flem bir g\u00fcn i\u00e7erisinde tamamlanmaktad\u0131r. Anjiyografi i\u015flemi sonras\u0131 kanama kontrol\u00fcn\u00fcn sa\u011flanmas\u0131 amac\u0131yla birka\u00e7 saat istirahat etmeniz gerekece\u011finden o g\u00fcn i\u00e7in ek bir program yapmaman\u0131z uygun olacakt\u0131r.<\/span><\/p>\n

\u0130triyum-90 Mikrok\u00fcre Tedavisi \u0130\u015flemi<\/b><\/span><\/p>\n

Prosed\u00fcr<\/b><\/span><\/p>\n

Y-90 <\/span>mikrok\u00fcre tedavisi; N\u00fckleer T\u0131p ve Giri\u015fimsel Radyoloji Uzman\u0131 Hekimlerin birlikte g\u00f6rev ald\u0131\u011f\u0131, multidisipliner bir uygulamad\u0131r. <\/span>Y-90 <\/span>mikrok\u00fcre tedavisi, karaci\u011fer atardamar\u0131na yerle\u015ftirilen kateter yoluyla yap\u0131lmaktad\u0131r. N\u00fckleer t\u0131p \u00fcnitesinde sizin i\u00e7in uygun olan dozda haz\u0131rlanan mikrok\u00fcreler, \u00fcretici firma taraf\u0131ndan sa\u011flanan uygulama kitlerine yerle\u015ftirilir ve ard\u0131ndan anjiyografi \u00fcnitesinde giri\u015fimsel radyolog taraf\u0131ndan kateter yoluyla yava\u015f enjeksiyon \u015feklinde uygulan\u0131r. <\/span><\/p>\n

Tedavi Sonras\u0131 Y-90 Mikrok\u00fcre G\u00f6r\u00fcnt\u00fcleme (Bremsstrahlung Sintigrafi ve SPECT\/BT veya Y-90 PET\/BT)<\/b><\/span> <\/b><\/p>\n

Tedavi sonras\u0131nda <\/span>Y-90<\/span> mikrok\u00fcrelerin tutulum yerlerinin saptanmas\u0131, akci\u011fer ve mide-ba\u011f\u0131rsak sistemi gibi, hedef d\u0131\u015f\u0131 b\u00f6lgelerde <\/span>Y-90 mikrok\u00fcre tutulumunu de\u011ferlendirmek ve t\u00fcm\u00f6r dozunu belirlemek i\u00e7in, n\u00fckleer t\u0131p klini\u011finde sintigrafik g\u00f6r\u00fcnt\u00fclemeniz yap\u0131lacakt\u0131r.<\/span><\/p>\n

Y-90 mikrok\u00fcre<\/span> tedavisi g\u00fcn\u00fcbirlik uygulanabilecek bir tedavidir. Bununla birlikte, olgular\u0131m\u0131zda s\u0131kl\u0131kla ba\u015fka sa\u011fl\u0131k sorunlar\u0131 da bulunabilmektedir. Bu nedenle hastalar\u0131m\u0131z\u0131n 1 gece hastanede g\u00f6zlem alt\u0131nda tutulmas\u0131 yararl\u0131 olacakt\u0131r. Hastalar\u0131m\u0131za tedavi g\u00fcn\u00fc gerekli g\u00f6r\u00fcld\u00fc\u011f\u00fc takdirde; analjezik ve antiemetik ila\u00e7lar, proton pompa inhibit\u00f6rleri ve steroidler koruyucu olarak kullan\u0131labilmektedir.<\/span><\/p>\n

Takip <\/b><\/span><\/p>\n

N\u00fckleer t\u0131p uzman\u0131n\u0131z tedavi sonras\u0131nda kontrol muayenesi i\u00e7in size randevu verecektir. Bu randevunuza sizden istenilen kan testleri ile birlikte gelmeyi unutmay\u0131n\u0131z.<\/span><\/p>\n

[\/et_pb_accordion_item][\/et_pb_accordion][et_pb_code _builder_version=”4.4.8″][\/et_pb_code][et_pb_button button_url=”@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9saW5rX3VybF9wYWdlIiwic2V0dGluZ3MiOnsicG9zdF9pZCI6IjIyODMifX0=@” button_text=”DIAGNOSIS: 99M TC-MAA LIVER PERFUSION SYNTIGRAPHY – Click for detailed information.” _builder_version=”4.4.8″ _dynamic_attributes=”button_url” hover_enabled=”0″][\/et_pb_button][et_pb_button button_url=”@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9saW5rX3VybF9wYWdlIiwic2V0dGluZ3MiOnsicG9zdF9pZCI6IjIzOTEifX0=@” button_text=”TREATMENT: YTTRIUM-90 MICRO-SPHERE TREATMENT – Click for detailed information.” _builder_version=”4.4.8″ _dynamic_attributes=”button_url” hover_enabled=”0″][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.4.8″ background_color=”rgba(0,0,0,0)” background_image=”https:\/\/www.intheranostics.com\/wp-content\/uploads\/2020\/06\/metastatik_prostat_kanseri.jpg” custom_padding=”100px||100px||false|false” locked=”off”][et_pb_fullwidth_header title=”Liver Tumors” text_orientation=”center” content_max_width_last_edited=”off|desktop” _builder_version=”4.4.8″ title_font_size=”50px” content_font_size=”41px” subhead_font=”|700|||||||” subhead_font_size=”38px” subhead_line_height=”1.1em” background_enable_color=”off” background_enable_image=”off” custom_margin=”||||false|false” custom_padding=”||||false|false” animation_style=”slide” animation_direction=”bottom”][\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.4.8″ custom_margin=”0px||0px||false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_row _builder_version=”4.4.8″ custom_margin=”0px||||false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”4.4.8″][et_pb_divider divider_weight=”0px” _builder_version=”4.4.8″ use_background_color_gradient=”on” background_color_gradient_start=”#8dd2e1″ background_color_gradient_end=”#23afca” background_color_gradient_direction=”90deg” width=”50%” module_alignment=”center” height=”10px”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″][et_pb_row admin_label=”row” _builder_version=”4.4.8″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”||||false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” […]<\/p>\n","protected":false},"author":6,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"

[et_pb_section fb_built=\"1\" fullwidth=\"on\" _builder_version=\"4.4.8\" background_color=\"rgba(0,0,0,0)\" background_image=\"https:\/\/www.intheranostics.com\/wp-content\/uploads\/2020\/06\/metastatik_prostat_kanseri.jpg\" custom_padding=\"100px||100px||false|false\" locked=\"off\"][et_pb_fullwidth_header title=\"Liver Tumors\" text_orientation=\"center\" content_max_width_last_edited=\"off|desktop\" _builder_version=\"4.4.8\" title_font_size=\"50px\" content_font_size=\"41px\" subhead_font=\"|700|||||||\" subhead_font_size=\"38px\" subhead_line_height=\"1.1em\" background_enable_color=\"off\" background_enable_image=\"off\" custom_margin=\"||||false|false\" custom_padding=\"||||false|false\" animation_style=\"slide\" animation_direction=\"bottom\"][\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=\"1\" _builder_version=\"4.4.8\" custom_margin=\"0px||0px||false|false\" custom_padding=\"0px|0px|0px|0px|false|false\"][et_pb_row _builder_version=\"4.4.8\" custom_margin=\"0px||||false|false\" custom_padding=\"0px|0px|0px|0px|false|false\"][et_pb_column type=\"4_4\" _builder_version=\"4.4.8\"][et_pb_divider divider_weight=\"0px\" _builder_version=\"4.4.8\" use_background_color_gradient=\"on\" background_color_gradient_start=\"#8dd2e1\" background_color_gradient_end=\"#23afca\" background_color_gradient_direction=\"90deg\" width=\"50%\" module_alignment=\"center\" height=\"10px\"][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\"1\" admin_label=\"section\" _builder_version=\"3.22\"][et_pb_row admin_label=\"row\" _builder_version=\"4.4.8\" background_size=\"initial\" background_position=\"top_left\" background_repeat=\"repeat\" custom_margin=\"||||false|false\" custom_padding=\"0px|0px|0px|0px|false|false\"][et_pb_column type=\"4_4\" _builder_version=\"3.25\" custom_padding=\"|||\" custom_padding__hover=\"|||\"][et_pb_text _builder_version=\"4.4.8\"]<\/p>

Most of the\u00a0liver tumors<\/strong>\u00a0cannot be surgically removed because of their large size or proximity to life-threatening structures. Sometimes, the disease can cause small but many tumors to spread to the liver. In this case, surgery is both very risky and not practical. Surgical removal is not possible in two-thirds of primary liver cancer patients and more than 90 percent of patients with metastatic (secondary) liver cancer for these reasons. In patients with inoperable liver cancer, one of the treatment options is Yttrium-90 microsphere treatment.<\/p>

[\/et_pb_text][et_pb_accordion disabled_on=\"on|on|on\" _builder_version=\"4.4.8\" disabled=\"on\"][et_pb_accordion_item title=\"TEDAV\u0130 PLANLAMASI - 99MTC-MAA KARACI\u011eER PERF\u00dcZYON S\u0130NT\u0130GRAF\u0130S\u0130\" open=\"on\" open_toggle_text_color=\"#0ca7c5\" _builder_version=\"4.4.8\" toggle_font=\"|700|||||||\" toggle_font_size=\"18px\"]<\/p>

Tc-99m MAA Karaci\u011fer Perf\u00fczyon Sintigrafisi Nedir, T\u00fcm\u00f6r Oda\u011f\u0131n\u0131 Nas\u0131l G\u00f6sterir?<\/b><\/span><\/p>

Teranostik<\/b>; t\u0131p d\u00fcnyas\u0131nda yeni ve geli\u015fmekte olan bir aland\u0131r. G\u00f6r\u00fcnt\u00fcleme ve tedavinin tek bir sistem \u00fczerinden ger\u00e7ekle\u015ftirilmesini esas al\u0131r, spesifik tedaviye ve tedavinin takibine e\u015f zamanl\u0131 olarak izin verir. <\/span><\/p>

Karaci\u011fer kanserlerinde, tedavi \u00f6ncesi prova amac\u0131yla yap\u0131lan Tc-99m MAA karaci\u011fer perf\u00fczyon sintigrafisi<\/b> ile akci\u011fer ve mide-ba\u011f\u0131rsak sistemine olan ka\u00e7aklar y\u00fcksek duyarl\u0131l\u0131kta saptanabilmekte ve optimum tedavi dozu planlanabilmektedir. Di\u011fer yandan \u0130trium-90 (Y-90) mikrok\u00fcre tedavisi<\/b> ile bu t\u00fcm\u00f6ral dokular\u0131n hedefe y\u00f6nelik tedavisi yap\u0131labilmektedir. <\/span>Bu, teranostik uygulamalar i\u00e7in olduk\u00e7a ba\u015far\u0131l\u0131 ve yeni bir y\u00f6ntemdir. <\/span><\/p>

Karaci\u011fer atardamar\u0131 (hepatik arter) yoluyla yap\u0131lan tedavilerde, karaci\u011ferin iki farkl\u0131 damardan beslenmesi avantaj\u0131ndan faydalan\u0131lmaktad\u0131r. 30 y\u0131l\u0131 a\u015fk\u0131n s\u00fcredir bu fark, kanser ila\u00e7lar\u0131n\u0131n karaci\u011fer damar\u0131 yoluyla uygulanmas\u0131na imkan tan\u0131m\u0131\u015ft\u0131r. Transarteriyel radyoembolizasyon (TARE) olarak da isimlendirilen Y-90 mikrok\u00fcre tedavisi, karaci\u011ferin hem kendisinden kaynaklanan hem de metastatik kanserleri i\u00e7in etkili bir tedavidir ve ameliyat veya di\u011fer b\u00f6lgesel tedavilerin uygulanamad\u0131\u011f\u0131 hastalar\u0131m\u0131zda, takip eden hekiminin \u00f6nerisi ile daha iyi sa\u011f kal\u0131m ve azalm\u0131\u015f hastal\u0131k y\u00fck\u00fcne ula\u015fmak amac\u0131yla kullan\u0131labilir.<\/span><\/p>

Bir hasta Y-90 mikrok\u00fcre tedavisi i\u00e7in aday olarak se\u00e7ildikten sonra, ilk olarak anjiyografik de\u011ferlendirme yap\u0131l\u0131r. Bu i\u015flem ile organ anatomisi ve anatomik farkl\u0131l\u0131klar tan\u0131mlan\u0131r, karaci\u011fer dola\u015f\u0131m\u0131 de\u011ferlendirilerek karaci\u011fer harici damarlar\u0131n t\u0131kanmas\u0131\/embolizasyonu ger\u00e7ekle\u015ftirilir. Anjiyografi i\u015flemi ile damar haritalamas\u0131n\u0131n tamamlanmas\u0131n\u0131 takiben, Y-90 mikrok\u00fcre tedavisinin provas\u0131 olan ve akci\u011fer\/mide-ba\u011f\u0131rsak sistemine ka\u00e7aklar\u0131n ara\u015ft\u0131r\u0131ld\u0131\u011f\u0131 ve en uygun tedavi dozunun planlanmas\u0131na imkan sa\u011flayan Tc-99m MAA karaci\u011fer perf\u00fczyon sintigrafisi<\/b> \u00e7al\u0131\u015fmas\u0131 yap\u0131l\u0131r.<\/span><\/p>

Tc-99m MAA Karaci\u011fer Perf\u00fczyon Sintigrafisi Kimlere Uygulan\u0131r?<\/b><\/span><\/p>

Tc-99m MAA karaci\u011fer perf\u00fczyon sintigrafisi, Y-90 mikrok\u00fcre tedavisine aday olgularda uygulan\u0131r. Tedavi \u00f6ncesi hastaya \u00f6zel planlamay\u0131 m\u00fcmk\u00fcn k\u0131lan, tan\u0131sal anjiyografi i\u015flemi s\u0131ras\u0131nda yap\u0131lan bir g\u00f6r\u00fcnt\u00fcleme y\u00f6ntemidir. <\/span><\/p>

Tc-99m MAA Karaci\u011fer Perf\u00fczyon Sintigrafisi G\u00fcvenli midir?<\/b><\/span><\/p>

Tc-99m MAA karaci\u011fer perf\u00fczyon sintigrafisi i\u015flemi, d\u00fc\u015f\u00fck dozlarda radyasyonun kullan\u0131ld\u0131\u011f\u0131, g\u00fcvenli bir g\u00f6r\u00fcnt\u00fcleme y\u00f6ntemidir. Birlikte yap\u0131lacak anjiyografi i\u015flemine ait \u00f6neri ve bilgilendirmeler ise size giri\u015fimsel radyoloji uzman\u0131m\u0131z taraf\u0131ndan verilecektir. Her iki i\u015flem, kullan\u0131lan radyasyon nedeniyle hamile hastalar\u0131m\u0131zda kesinlikle uygulanamaz. <\/span><\/p>

Tc-99m MAA Karaci\u011fer Perf\u00fczyon Sintigrafisi \u00d6ncesi Haz\u0131rl\u0131k <\/b><\/span><\/p>

Tc-99m MAA karaci\u011fer perf\u00fczyon sintigrafisi i\u00e7in \u00f6zel bir hasta haz\u0131rl\u0131\u011f\u0131na gerek yoktur. Bununla birlikte yap\u0131lacak anjiyografi i\u015flemine ait \u00f6neri ve bilgilendirmeler size giri\u015fimsel radyoloji \u00fcnitesi personelimiz taraf\u0131ndan yap\u0131lacakt\u0131r.<\/span><\/p>

Tc-99m MAA Karaci\u011fer Perf\u00fczyon Sintigrafisi Nas\u0131l Uygulan\u0131r?<\/b><\/span><\/p>

Tc-99m MAA karaci\u011fer perf\u00fczyon sintigrafisi; N\u00fckleer T\u0131p ve Giri\u015fimsel Radyoloji Uzmanlar\u0131n\u0131n birlikte ger\u00e7ekle\u015ftirdikleri, multidisipliner bir uygulamad\u0131r<\/b>.<\/span><\/p>

Y-90 mikrok\u00fcre tedavisi \u00f6ncesi temel a\u015famalardan ilki; giri\u015fimsel radyoloji \u00fcnitesinde t\u00fcm\u00f6r\u00fc besleyen damarlar\u0131 de\u011ferlendirmek i\u00e7in yap\u0131lan anjiyografi i\u015flemidir. Bu i\u015flem tamamland\u0131ktan sonra mevcut anjiyografi kateterinden d\u00fc\u015f\u00fck dozda Tc-99m MAA'n\u0131n enjeksiyonu yap\u0131l\u0131r. Bu i\u015flem s\u0131ras\u0131nda herhangi bir \u015fey hissedilmemektedir. Daha sonra akci\u011fer ve karaci\u011ferinizi g\u00f6r\u00fcnt\u00fclemek \u00fczere N\u00fckleer T\u0131p Klini\u011fine transferiniz ger\u00e7ekle\u015ftirilecektir. Bu i\u015flem s\u0131ras\u0131nda gama kamera<\/b> ad\u0131 verilen cihaza ait \u00f6zel yatakta s\u0131rt \u00fcst\u00fc uzanman\u0131z istenecektir. Sintigrafi i\u015flemi tamamland\u0131ktan sonra, anjiyografiye ait takibiniz yap\u0131lacak ve sa\u011fl\u0131k personelimizin bilgi vermesiyle hastaneden g\u00fcvenle ayr\u0131labileceksiniz. <\/span><\/p>

\u0130la\u00e7 verildikten sonra ilk 12 saat k\u00fc\u00e7\u00fck \u00e7ocuklarla ve hamile kad\u0131nlarla temastan ka\u00e7\u0131nman\u0131z gerekti\u011fini l\u00fctfen unutmay\u0131n\u0131z. <\/span>G\u00f6r\u00fcnt\u00fcleriniz N\u00fckleer T\u0131p Uzmanlar\u0131m\u0131z taraf\u0131ndan de\u011ferlendirilecek ve tedavi planlaman\u0131z s\u0131ras\u0131nda kullan\u0131lacakt\u0131r. <\/span><\/p>

[\/et_pb_accordion_item][et_pb_accordion_item title=\"TEDAV\u0130 H\u0130ZMETLER\u0130 - \u0130TRIYUM-90 MIKROK\u00dcRE TEDAV\u0130S\u0130\" open_toggle_text_color=\"#0ca7c5\" _builder_version=\"4.4.8\" toggle_font=\"|700|||||||\" toggle_font_size=\"18px\" open=\"off\"]<\/p>

\u0130triyum-90 Mikrok\u00fcre Tedavisi Nedir, Nas\u0131l Tedavi Eder?<\/b><\/span><\/p>

Teranostik <\/b>t\u0131p d\u00fcnyas\u0131nda yeni geli\u015fmekte olan bir aland\u0131r. T\u00fcm\u00f6re \u00f6zg\u00fcl bir ila\u00e7 ile g\u00f6r\u00fcnt\u00fcleme yaparak saptanan t\u00fcm\u00f6r ve metastazlar\u0131n\u0131n, nereye gidece\u011fi-ne kadar gidece\u011fi ve hastal\u0131kl\u0131 dokuyu etkileme g\u00fcc\u00fc \u00f6nceden bilinen yine \u00f6zg\u00fcl bir ila\u00e7 ile tedavi edilebildi\u011fi bir yakla\u015f\u0131md\u0131r. Bu yakla\u015f\u0131m, geleneksel t\u0131ptan ki\u015fiye \u00f6zg\u00fc \u00e7a\u011fda\u015f t\u0131p uygulamalar\u0131na ge\u00e7i\u015f yap\u0131lmas\u0131n\u0131 sa\u011flamaktad\u0131r.<\/span><\/p>

Karaci\u011fer kanserlerinde, tedavi \u00f6ncesi prova amac\u0131yla yap\u0131lan 99mTc-MAA karaci\u011fer perf\u00fczyon sintigrafisi<\/b> ile akci\u011fer ve mide-ba\u011f\u0131rsak sistemine olan ka\u00e7aklar y\u00fcksek duyarl\u0131l\u0131kla saptanabilmekte ve optimum tedavi dozu planlanabilmektedir. Di\u011fer yandan \u0130trium-90 (Y-90) mikrok\u00fcre<\/b> tedavisi ile bu t\u00fcm\u00f6ral dokular\u0131n hedefe y\u00f6nelik tedavisi yap\u0131labilmektedir. <\/span>Bu, teranostik uygulamalar i\u00e7in olduk\u00e7a ba\u015far\u0131l\u0131 ve yeni bir y\u00f6ntemdir. <\/span><\/p>

Karaci\u011fer atardamar\u0131 (hepatik arter) yoluyla yap\u0131lan tedavilerde, karaci\u011ferin iki farkl\u0131 damardan beslenmesi avantaj\u0131ndan faydalan\u0131lmaktad\u0131r. 30 y\u0131l\u0131 a\u015fk\u0131n s\u00fcredir bu fark, kanser ila\u00e7lar\u0131n\u0131n karaci\u011fer damar\u0131 yoluyla uygulanmas\u0131na imkan tan\u0131m\u0131\u015ft\u0131r. Transarteryel radyoembolizasyon (TARE) olarak da isimlendirilen Y-90 mikrok\u00fcre tedavisi, karaci\u011ferin hem kendisinden kaynaklanan hem de metastatik kanserleri i\u00e7in etkili bir tedavidir ve ameliyat veya di\u011fer b\u00f6lgesel tedavilerin uygulanamad\u0131\u011f\u0131 hastalar\u0131m\u0131zda, takip eden hekiminin \u00f6nerisi ile daha iyi sa\u011f kal\u0131m ve azalm\u0131\u015f hastal\u0131k y\u00fck\u00fcne ula\u015fmak amac\u0131yla kullan\u0131labilir.<\/span><\/p>

Y-90, beta radyasyonu yayar ve t\u00fcm\u00f6r b\u00f6lgesine ula\u015ft\u0131\u011f\u0131nda, h\u00fccre \u00f6l\u00fcm\u00fc ve t\u00fcm\u00f6r nekrozuna neden olur. Y-90 izotopunun dokuda ilerlemesi yakla\u015f\u0131k 1 cm'dir ve bu k\u0131sa menzille \u00e7evre sa\u011fl\u0131kl\u0131 karaci\u011fer dokusunun ald\u0131\u011f\u0131 radyasyon dozu hasta lehine s\u0131n\u0131rland\u0131r\u0131lm\u0131\u015f olur. Buna ek olarak, beta radyasyonunun b\u00f6ylesine k\u0131sa menzili, hasta bak\u0131m\u0131n\u0131 yapan t\u0131bbi personel ve aile \u00fcyeleri i\u00e7in de hastay\u0131 daha g\u00fcvenli k\u0131lmaktad\u0131r.<\/span><\/p>

\u0130triyum-90 Mikrok\u00fcre Tedavisi Kimlere Uygulan\u0131r?<\/b><\/span><\/p>

Y-90 mikrok\u00fcre tedavisi; klasik olarak ameliyatla \u00e7\u0131kart\u0131lamayan, karaci\u011ferin kendisinden kaynaklanan (primer) veya metastatik karaci\u011fer kanserlerinde uygulanmaktad\u0131r.<\/span><\/p>

\u0130triyum-90 Mikrok\u00fcre Tedavisi G\u00fcvenli midir?<\/b><\/span><\/p>

Y-90 mikrok\u00fcre tedavisi tipik olarak iyi tolere edilen g\u00fcvenli bir tedavidir. <\/span>Y-90; saf beta par\u00e7ac\u0131\u011f\u0131 yayd\u0131g\u0306\u0131 ve gama radyasyonu bulunmad\u0131g\u0306\u0131 i\u00e7in tedavi sonras\u0131 hasta izolasyonu ve \u00f6zel bir radyasyondan korunma \u00f6nlemi gerekmemektedir.<\/span><\/p>

Y-90 mikrok\u00fcre tedavisinin en s\u0131k yan etkisi; yorgunluk, bulant\u0131, kusma ve\/veya kar\u0131n a\u011fr\u0131s\u0131 ile karakterize olan post-radyoembolizasyon sendromudur. \u015eikayetler, analjezik ve antiemetik ila\u00e7lar ile kolayl\u0131kla tedavi edilebilir. <\/span><\/p>

Ayr\u0131ca, tecr\u00fcbeli eller ile g\u00f6r\u00fclme s\u0131kl\u0131\u011f\u0131 daha da azalabilen, \u00e7ok daha nadir di\u011fer yan etkilere de rastlanabilmektedir. \u0130yi bir tedavi planlama ve \u00f6n planlama anjiyografisinde, ilgili damarlar\u0131n profilaktik embolizasyonu veya uygun kateterizasyon teknikleri ile bu komplikasyonlar\u0131n da \u00f6n\u00fcne ge\u00e7ilebilmektedir. <\/span><\/p>

\u0130triyum-90 Mikrok\u00fcre Tedavisi \u00d6ncesi Haz\u0131rl\u0131k <\/b><\/span><\/p>

Y-90 mikrok\u00fcre tedavisine uygun hasta se\u00e7imi; genel cerrah, medikal onkolog, gastroenterolog, giri\u015fimsel radyolog ve n\u00fckleer t\u0131p uzman\u0131ndan olu\u015fan multidisipliner t\u00fcm\u00f6r kurulu taraf\u0131ndan yap\u0131lmaktad\u0131r. <\/span><\/p>

Tedavi \u00f6ncesinde, ilk ad\u0131m olarak genel sa\u011fl\u0131k durumunuz ve performans\u0131n\u0131z, karaci\u011fer ve b\u00f6brek fonksiyonlar\u0131n\u0131z\u0131 g\u00f6steren kan testi sonu\u00e7lar\u0131n\u0131z, patoloji ve ameliyat raporlar\u0131n\u0131z, daha \u00f6nce ald\u0131\u011f\u0131n\u0131z tedaviler ve g\u00f6r\u00fcnt\u00fclemeleriniz (FDG-PET\/BT, MR, BT vb.) de\u011ferlendirilecektir. <\/span><\/p>

Klinik \u00f6n de\u011ferlendirmede tedaviye uygun oldu\u011funuz d\u00fc\u015f\u00fcn\u00fcl\u00fcr ise tedavinizi planlamak amac\u0131yla; anjiyografi \u00fcnitesi ve n\u00fckleer t\u0131p klini\u011finde karaci\u011fer damarlar\u0131n\u0131za y\u00f6nelik anjiyografi ve karaci\u011fer perf\u00fczyon sintigrafisi \u00e7al\u0131\u015fmalar\u0131 ger\u00e7ekle\u015ftirilecektir. Her iki i\u015flem bir g\u00fcn i\u00e7erisinde tamamlanmaktad\u0131r. Anjiyografi i\u015flemi sonras\u0131 kanama kontrol\u00fcn\u00fcn sa\u011flanmas\u0131 amac\u0131yla birka\u00e7 saat istirahat etmeniz gerekece\u011finden o g\u00fcn i\u00e7in ek bir program yapmaman\u0131z uygun olacakt\u0131r.<\/span><\/p>

\u0130triyum-90 Mikrok\u00fcre Tedavisi \u0130\u015flemi<\/b><\/span><\/p>

Prosed\u00fcr<\/b><\/span><\/p>

Y-90 <\/span>mikrok\u00fcre tedavisi; N\u00fckleer T\u0131p ve Giri\u015fimsel Radyoloji Uzman\u0131 Hekimlerin birlikte g\u00f6rev ald\u0131\u011f\u0131, multidisipliner bir uygulamad\u0131r. <\/span>Y-90 <\/span>mikrok\u00fcre tedavisi, karaci\u011fer atardamar\u0131na yerle\u015ftirilen kateter yoluyla yap\u0131lmaktad\u0131r. N\u00fckleer t\u0131p \u00fcnitesinde sizin i\u00e7in uygun olan dozda haz\u0131rlanan mikrok\u00fcreler, \u00fcretici firma taraf\u0131ndan sa\u011flanan uygulama kitlerine yerle\u015ftirilir ve ard\u0131ndan anjiyografi \u00fcnitesinde giri\u015fimsel radyolog taraf\u0131ndan kateter yoluyla yava\u015f enjeksiyon \u015feklinde uygulan\u0131r. <\/span><\/p>

Tedavi Sonras\u0131 Y-90 Mikrok\u00fcre G\u00f6r\u00fcnt\u00fcleme (Bremsstrahlung Sintigrafi ve SPECT\/BT veya Y-90 PET\/BT)<\/b><\/span> <\/b><\/p>

Tedavi sonras\u0131nda <\/span>Y-90<\/span> mikrok\u00fcrelerin tutulum yerlerinin saptanmas\u0131, akci\u011fer ve mide-ba\u011f\u0131rsak sistemi gibi, hedef d\u0131\u015f\u0131 b\u00f6lgelerde <\/span>Y-90 mikrok\u00fcre tutulumunu de\u011ferlendirmek ve t\u00fcm\u00f6r dozunu belirlemek i\u00e7in, n\u00fckleer t\u0131p klini\u011finde sintigrafik g\u00f6r\u00fcnt\u00fclemeniz yap\u0131lacakt\u0131r.<\/span><\/p>

Y-90 mikrok\u00fcre<\/span> tedavisi g\u00fcn\u00fcbirlik uygulanabilecek bir tedavidir. Bununla birlikte, olgular\u0131m\u0131zda s\u0131kl\u0131kla ba\u015fka sa\u011fl\u0131k sorunlar\u0131 da bulunabilmektedir. Bu nedenle hastalar\u0131m\u0131z\u0131n 1 gece hastanede g\u00f6zlem alt\u0131nda tutulmas\u0131 yararl\u0131 olacakt\u0131r. Hastalar\u0131m\u0131za tedavi g\u00fcn\u00fc gerekli g\u00f6r\u00fcld\u00fc\u011f\u00fc takdirde; analjezik ve antiemetik ila\u00e7lar, proton pompa inhibit\u00f6rleri ve steroidler koruyucu olarak kullan\u0131labilmektedir.<\/span><\/p>

Takip <\/b><\/span><\/p>

N\u00fckleer t\u0131p uzman\u0131n\u0131z tedavi sonras\u0131nda kontrol muayenesi i\u00e7in size randevu verecektir. Bu randevunuza sizden istenilen kan testleri ile birlikte gelmeyi unutmay\u0131n\u0131z.<\/span><\/p>

[\/et_pb_accordion_item][\/et_pb_accordion][et_pb_code _builder_version=\"4.4.8\"][\/et_pb_code][et_pb_button button_url=\"@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9saW5rX3VybF9wYWdlIiwic2V0dGluZ3MiOnsicG9zdF9pZCI6IjE2ODAifX0=@\" button_text=\"DIAGNOSIS: 99MTC-MAA LIVER PERFUSION SYNTIGRAPHY - Click for detailed information.\" _builder_version=\"4.4.8\" _dynamic_attributes=\"button_url\"][\/et_pb_button][et_pb_button button_url=\"@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9saW5rX3VybF9wYWdlIiwic2V0dGluZ3MiOnsicG9zdF9pZCI6IjE2ODEifX0=@\" button_text=\"TREATMENT: YTTRIUM-90 MICRO-SPHERE TREATMENT - Click for detailed information.\" _builder_version=\"4.4.8\" _dynamic_attributes=\"button_url\" hover_enabled=\"0\"][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","_et_gb_content_width":"","footnotes":""},"class_list":["post-2425","page","type-page","status-publish","hentry"],"yoast_head":"\nLiver Tumors - Prof intheranostics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.intheranostics.com\/prof\/en\/liver-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Liver Tumors - Prof intheranostics\" \/>\n<meta property=\"og:description\" content=\"[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.4.8″ background_color=”rgba(0,0,0,0)” background_image=”https:\/\/www.intheranostics.com\/wp-content\/uploads\/2020\/06\/metastatik_prostat_kanseri.jpg” custom_padding=”100px||100px||false|false” locked=”off”][et_pb_fullwidth_header title=”Liver Tumors” text_orientation=”center” content_max_width_last_edited=”off|desktop” _builder_version=”4.4.8″ title_font_size=”50px” content_font_size=”41px” subhead_font=”|700|||||||” subhead_font_size=”38px” subhead_line_height=”1.1em” background_enable_color=”off” background_enable_image=”off” custom_margin=”||||false|false” custom_padding=”||||false|false” animation_style=”slide” animation_direction=”bottom”][\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.4.8″ custom_margin=”0px||0px||false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_row _builder_version=”4.4.8″ custom_margin=”0px||||false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”4.4.8″][et_pb_divider divider_weight=”0px” _builder_version=”4.4.8″ use_background_color_gradient=”on” background_color_gradient_start=”#8dd2e1″ background_color_gradient_end=”#23afca” background_color_gradient_direction=”90deg” width=”50%” module_alignment=”center” height=”10px”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″][et_pb_row admin_label=”row” _builder_version=”4.4.8″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”||||false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.intheranostics.com\/prof\/en\/liver-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Prof intheranostics\" \/>\n<meta property=\"article:modified_time\" content=\"2020-10-09T14:35:46+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.intheranostics.com\/prof\/en\/liver-tumors\/\",\"url\":\"https:\/\/www.intheranostics.com\/prof\/en\/liver-tumors\/\",\"name\":\"Liver Tumors - Prof intheranostics\",\"isPartOf\":{\"@id\":\"https:\/\/www.intheranostics.com\/prof\/#website\"},\"datePublished\":\"2020-10-09T14:21:45+00:00\",\"dateModified\":\"2020-10-09T14:35:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.intheranostics.com\/prof\/en\/liver-tumors\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.intheranostics.com\/prof\/en\/liver-tumors\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.intheranostics.com\/prof\/en\/liver-tumors\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Ana sayfa\",\"item\":\"https:\/\/www.intheranostics.com\/prof\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Liver Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.intheranostics.com\/prof\/#website\",\"url\":\"https:\/\/www.intheranostics.com\/prof\/\",\"name\":\"Prof intheranostics\",\"description\":\"Internal Radionuclide Diagnosis & Therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.intheranostics.com\/prof\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Liver Tumors - Prof intheranostics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.intheranostics.com\/prof\/en\/liver-tumors\/","og_locale":"en_US","og_type":"article","og_title":"Liver Tumors - Prof intheranostics","og_description":"[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.4.8″ background_color=”rgba(0,0,0,0)” background_image=”https:\/\/www.intheranostics.com\/wp-content\/uploads\/2020\/06\/metastatik_prostat_kanseri.jpg” custom_padding=”100px||100px||false|false” locked=”off”][et_pb_fullwidth_header title=”Liver Tumors” text_orientation=”center” content_max_width_last_edited=”off|desktop” _builder_version=”4.4.8″ title_font_size=”50px” content_font_size=”41px” subhead_font=”|700|||||||” subhead_font_size=”38px” subhead_line_height=”1.1em” background_enable_color=”off” background_enable_image=”off” custom_margin=”||||false|false” custom_padding=”||||false|false” animation_style=”slide” animation_direction=”bottom”][\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.4.8″ custom_margin=”0px||0px||false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_row _builder_version=”4.4.8″ custom_margin=”0px||||false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”4.4.8″][et_pb_divider divider_weight=”0px” _builder_version=”4.4.8″ use_background_color_gradient=”on” background_color_gradient_start=”#8dd2e1″ background_color_gradient_end=”#23afca” background_color_gradient_direction=”90deg” width=”50%” module_alignment=”center” height=”10px”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″][et_pb_row admin_label=”row” _builder_version=”4.4.8″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”||||false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” […]","og_url":"https:\/\/www.intheranostics.com\/prof\/en\/liver-tumors\/","og_site_name":"Prof intheranostics","article_modified_time":"2020-10-09T14:35:46+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.intheranostics.com\/prof\/en\/liver-tumors\/","url":"https:\/\/www.intheranostics.com\/prof\/en\/liver-tumors\/","name":"Liver Tumors - Prof intheranostics","isPartOf":{"@id":"https:\/\/www.intheranostics.com\/prof\/#website"},"datePublished":"2020-10-09T14:21:45+00:00","dateModified":"2020-10-09T14:35:46+00:00","breadcrumb":{"@id":"https:\/\/www.intheranostics.com\/prof\/en\/liver-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.intheranostics.com\/prof\/en\/liver-tumors\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.intheranostics.com\/prof\/en\/liver-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Ana sayfa","item":"https:\/\/www.intheranostics.com\/prof\/en\/"},{"@type":"ListItem","position":2,"name":"Liver Tumors"}]},{"@type":"WebSite","@id":"https:\/\/www.intheranostics.com\/prof\/#website","url":"https:\/\/www.intheranostics.com\/prof\/","name":"Prof intheranostics","description":"Internal Radionuclide Diagnosis & Therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.intheranostics.com\/prof\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.intheranostics.com\/prof\/en\/wp-json\/wp\/v2\/pages\/2425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.intheranostics.com\/prof\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.intheranostics.com\/prof\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.intheranostics.com\/prof\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.intheranostics.com\/prof\/en\/wp-json\/wp\/v2\/comments?post=2425"}],"version-history":[{"count":3,"href":"https:\/\/www.intheranostics.com\/prof\/en\/wp-json\/wp\/v2\/pages\/2425\/revisions"}],"predecessor-version":[{"id":2444,"href":"https:\/\/www.intheranostics.com\/prof\/en\/wp-json\/wp\/v2\/pages\/2425\/revisions\/2444"}],"wp:attachment":[{"href":"https:\/\/www.intheranostics.com\/prof\/en\/wp-json\/wp\/v2\/media?parent=2425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}